Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches

[1]  M. Murad,et al.  Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. , 2013, Gastroenterology.

[2]  A. Lonardo,et al.  Potential for statins in the chemoprevention and management of hepatocellular carcinoma , 2012, Journal of gastroenterology and hepatology.

[3]  Deepa T. Patil,et al.  Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[4]  K. Cusi,et al.  The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease , 2012 .

[5]  J. Shieh,et al.  Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies , 2012, Gut.

[6]  P. O'Neil,et al.  Randomized Placebo‐Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM‐DM Study , 2012, Obesity.

[7]  K. Cusi,et al.  The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[8]  S. Klein,et al.  Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease , 2012, Hepatology.

[9]  E. Brunt,et al.  Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. , 2012, Journal of hepatology.

[10]  J. Hardies,et al.  Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease , 2012, Hepatology.

[11]  Zhi‐Jie Zheng,et al.  Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. , 2012, The Journal of clinical endocrinology and metabolism.

[12]  K. Cusi,et al.  Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. , 2012, Gastroenterology.

[13]  Qiwen Ben,et al.  Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: A systematic review and meta‐analysis of cohort studies , 2012, International journal of cancer.

[14]  J. Hardies,et al.  Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) , 2012, Diabetes Care.

[15]  G. Shulman,et al.  Mechanisms for Insulin Resistance: Common Threads and Missing Links , 2012, Cell.

[16]  L. Joosten,et al.  The inflammasome puts obesity in the danger zone. , 2012, Cell metabolism.

[17]  C. Palmeira,et al.  Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. , 2012, Free radical biology & medicine.

[18]  Christian Thoma,et al.  Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. , 2012, Journal of hepatology.

[19]  S. Burgess,et al.  Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. , 2011, Cell metabolism.

[20]  K. Akın,et al.  Some inflammatory cytokine levels, iron metabolism and oxidan stress markers in subjects with nonalcoholic steatohepatitis. , 2011, Clinical biochemistry.

[21]  G. Musso,et al.  Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity , 2011, Annals of medicine.

[22]  A. Feldstein,et al.  Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo‐controlled trial , 2011, Hepatology.

[23]  M. Cosentino,et al.  Lipid Targets During Statin Treatment in Dyslipidemic Patients Affected by Nonalcoholic Fatty Liver Disease , 2011, The American journal of the medical sciences.

[24]  M. Vivarelli,et al.  Glucagon‐like peptide‐1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high‐fat diet in nonalcoholic steatohepatitis , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[25]  F. Anania,et al.  GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy , 2011, PloS one.

[26]  K. Cusi,et al.  Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis , 2011, Hepatology.

[27]  H. Ginsberg,et al.  Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance , 2011, Trends in Endocrinology & Metabolism.

[28]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[29]  R. Green,et al.  Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. , 2011, Annals of hepatology.

[30]  Sarah A. Moore,et al.  Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss , 2011, Gut.

[31]  H. Makhlouf,et al.  Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality , 2011, Hepatology.

[32]  K. Kowdley,et al.  Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. , 2011, Clinics in liver disease.

[33]  P. Rosenthal,et al.  Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. , 2011, JAMA.

[34]  K. Gadde,et al.  Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.

[35]  J. Dillon,et al.  Systematic review of performance of non‐invasive biomarkers in the evaluation of non‐alcoholic fatty liver disease , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[36]  G. Farrell,et al.  Postprandial hyperinsulinemia is universal in non‐diabetic patients with nonalcoholic fatty liver disease , 2011, Journal of gastroenterology and hepatology.

[37]  M. Milburn,et al.  Plasma metabolomic profile in nonalcoholic fatty liver disease. , 2011, Metabolism: clinical and experimental.

[38]  K. Chayama,et al.  Postprandial insulin secretion pattern is associated with histological severity in non‐alcoholic fatty liver disease patients without prior known diabetes mellitus , 2011, Journal of gastroenterology and hepatology.

[39]  K. Sung,et al.  Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. , 2011, The Journal of clinical endocrinology and metabolism.

[40]  M. Budoff,et al.  Atorvastatin and Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease: The St Francis Heart Study Randomized Clinical Trial , 2011, The American Journal of Gastroenterology.

[41]  Joel Z Stengel,et al.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.

[42]  D. Mikhailidis,et al.  Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis , 2010, The Lancet.

[43]  N. Chalasani,et al.  Exenatide in the Treatment of Diabetic Patients With Non-Alcoholic Steatohepatitis: A Case Series , 2010, The American Journal of Gastroenterology.

[44]  P. Crotty,et al.  Transient elastography for the noninvasive assessment of liver fibrosis: a multicentre Canadian study. , 2010, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[45]  H. Conjeevaram,et al.  Meta‐analysis: insulin sensitizers for the treatment of non‐alcoholic steatohepatitis , 2010, Alimentary pharmacology & therapeutics.

[46]  A. Feldstein,et al.  Novel Insights into the Pathophysiology of Nonalcoholic Fatty Liver Disease , 2010, Seminars in liver disease.

[47]  B. Neuschwander‐Tetri,et al.  Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease , 2010, Hepatology.

[48]  G. Booth,et al.  Newly diagnosed diabetes mellitus as a risk factor for serious liver disease , 2010, Canadian Medical Association Journal.

[49]  B. Neuschwander‐Tetri.  Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites , 2010, Hepatology.

[50]  D. Reboussin,et al.  Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes , 2010, Diabetes Care.

[51]  Vincent Wai-Sun Wong,et al.  Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years , 2010, Gut.

[52]  K. Cusi.  The Role of Adipose Tissue and Lipotoxicity in the Pathogenesis of Type 2 Diabetes , 2010, Current diabetes reports.

[53]  B. S. Mohammed,et al.  Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. , 2010, The Journal of clinical endocrinology and metabolism.

[54]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[55]  S. Harrison,et al.  Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection , 2010, Hepatology.

[56]  F. Anania,et al.  Glucagon‐like peptide‐1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway , 2010, Hepatology.

[57]  C. Day.  Genetic and Environmental Susceptibility to Non-Alcoholic Fatty Liver Disease , 2010, Digestive Diseases.

[58]  S. Caldwell,et al.  The Natural History of Non-Alcoholic Fatty Liver Disease , 2010, Digestive Diseases.

[59]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[60]  Manal M. Hassan,et al.  Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma , 2010, Cancer.

[61]  S. Klein,et al.  Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications , 2010, Hepatology.

[62]  Greger Lindberg,et al.  Decreased survival of subjects with elevated liver function tests during a 28‐year follow‐up , 2010, Hepatology.

[63]  K. Chayama,et al.  Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH , 2010, Journal of Gastroenterology.

[64]  T. Barrientos-Gutiérrez,et al.  Bariatric surgery for non-alcoholic steatohepatitis in obese patients. , 2010, The Cochrane database of systematic reviews.

[65]  K. Cusi,et al.  Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. , 2010, The Journal of clinical endocrinology and metabolism.

[66]  D. Matthews,et al.  Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue , 2009, Diabetes, obesity & metabolism.

[67]  S. Klein,et al.  Diet and Exercise Interventions Reduce Intrahepatic Fat Content and Improve Insulin Sensitivity in Obese Older Adults , 2009, Obesity.

[68]  D. Lawlor,et al.  Alanine aminotransferase, γ‐glutamyltransferase (GGT) and all‐cause mortality: results from a population‐based Danish twins study alanine aminotransferase, GGT and mortality in elderly twins , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[69]  M. Rinella,et al.  Non-alcoholic fatty liver disease: is bariatric surgery the answer? , 2009, Clinics in liver disease.

[70]  K. Cusi.  Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. , 2009, Clinics in liver disease.

[71]  D. Torres,et al.  A Pilot Study Using Simvastatin in the Treatment of Nonalcoholic Steatohepatitis: A Randomized Placebo-controlled Trial , 2009, Journal of clinical gastroenterology.

[72]  J. George,et al.  Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss , 2009, Hepatology.

[73]  Ewald Moser,et al.  Abnormal hepatic energy homeostasis in type 2 diabetes , 2009, Hepatology.

[74]  A. Feldstein,et al.  Cytokeratin‐18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study , 2009, Hepatology.

[75]  Y. Yılmaz,et al.  Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. , 2009, World journal of gastroenterology.

[76]  F. Schick,et al.  Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. , 2009, Journal of hepatology.

[77]  F. Pattou,et al.  Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. , 2009, Gastroenterology.

[78]  J. Benson,et al.  The natural history of non-alcoholic fatty liver disease , 2006 .

[79]  J. Patrie,et al.  Intramitochondrial crystalline inclusions in nonalcoholic steatohepatitis , 2009, Hepatology.

[80]  Michael L. Johnson,et al.  Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. , 2009, Gastroenterology.

[81]  D. Reeds,et al.  Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. , 2009, Gastroenterology.

[82]  K. Cusi.  Nonalcoholic fatty liver disease in type 2 diabetes mellitus , 2009, Current opinion in endocrinology, diabetes, and obesity.

[83]  D. Huo,et al.  Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. , 2009, Journal of hepatology.

[84]  Chunhong Bai,et al.  Long-term follow-up of patients with nonalcoholic fatty liver. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[85]  Per Christoffersen,et al.  Final results of a long-term, clinical follow-up in fatty liver patients , 2009, Scandinavian journal of gastroenterology.

[86]  K. Birkeland,et al.  Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial , 2009, Scandinavian journal of gastroenterology.

[87]  B. Neuschwander‐Tetri,et al.  Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial , 2009, Hepatology.

[88]  J. Hoofnagle,et al.  Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitis , 2009, Alimentary pharmacology & therapeutics.

[89]  F. Schick,et al.  High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease , 2008, Gut.

[90]  P. Schauer,et al.  Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[91]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[92]  G. Aithal,et al.  Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. , 2008, Gastroenterology.

[93]  A. Baranova,et al.  A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH) , 2008, Obesity surgery.

[94]  M. Pérez-Carreras,et al.  A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[95]  C. Wai,et al.  A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH) , 2008, Hepatology international.

[96]  B. S. Mohammed,et al.  Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. , 2008, Gastroenterology.

[97]  G. Bedogni,et al.  Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis , 2008, Gut.

[98]  D. Klonoff,et al.  Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. , 2008, Current medical research and opinion.

[99]  James H. Lewis,et al.  Efficacy and safety of high‐dose pravastatin in hypercholesterolemic patients with well‐compensated chronic liver disease: Results of a prospective, randomized, double‐blind, placebo‐controlled, multicenter trial , 2007, Hepatology.

[100]  K. Pietiläinen,et al.  Liver fat in the metabolic syndrome. , 2007, The Journal of clinical endocrinology and metabolism.

[101]  A. Feldstein,et al.  Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: Present and future , 2007, Hepatology.

[102]  M. Holmqvist,et al.  Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. , 2007, Journal of hepatology.

[103]  K. Petersen,et al.  Disordered lipid metabolism and the pathogenesis of insulin resistance. , 2007, Physiological reviews.

[104]  E. Georgescu,et al.  Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. , 2007, Journal of gastrointestinal and liver diseases : JGLD.

[105]  B. Sharma,et al.  Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non‐alcoholic steatohepatitis , 2006, Journal of gastroenterology and hepatology.

[106]  Jimmy D Bell,et al.  Exercise training reduces fatty acid availability and improves the insulin sensitivity of glucose metabolism , 2006, Diabetologia.

[107]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[108]  M. Holmqvist,et al.  Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.

[109]  F. Chan,et al.  Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non‐alcoholic fatty liver disease , 2006, Alimentary pharmacology & therapeutics.

[110]  J. Browning.  Statins and hepatic steatosis: Perspectives from the Dallas Heart Study , 2006, Hepatology.

[111]  J. Gisbert,et al.  A pilot study of atorvastatin treatment in dyslipemid, non‐alcoholic fatty liver patients , 2006, Alimentary pharmacology & therapeutics.

[112]  E. Ravussin,et al.  Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. , 2006, Diabetes care.

[113]  A. Csendes,et al.  Histological Findings in the Liver Before and After Gastric Bypass , 2006, Obesity surgery.

[114]  M. Leshno,et al.  Double-Blind Randomized Placebo-Controlled Trial of Orlistat or the Treatment of Nonalcoholic Fatty Liver Disease , 2022 .

[115]  A. Burroughs,et al.  Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study , 2006, Current medical research and opinion.

[116]  M. Ekstedt,et al.  690 Statins in patients with elevated liver enzymes because of non-alcoholic fatty liver disease (NAFLD): A clinical and histopathological follow-up study , 2006 .

[117]  G. Choudhuri,et al.  Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis , 2006, Journal of gastroenterology and hepatology.

[118]  F. Anania,et al.  Exendin‐4, a glucagon‐like protein‐1 (GLP‐1) receptor agonist, reverses hepatic steatosis in ob/ob mice , 2006, Hepatology.

[119]  S. Summers,et al.  Ceramides in insulin resistance and lipotoxicity. , 2006, Progress in lipid research.

[120]  U. Akarca,et al.  Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment. , 2005, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[121]  S. Sanderson,et al.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.

[122]  Y. Tamura,et al.  Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. , 2005, The Journal of clinical endocrinology and metabolism.

[123]  J. Jessurun,et al.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.

[124]  G. Marchesini,et al.  A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease , 2005, The American Journal of Gastroenterology.

[125]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[126]  S. Sanderson,et al.  The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. , 2005, Journal of hepatology.

[127]  Jonathan C. Cohen,et al.  Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.

[128]  J. Clore,et al.  A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[129]  K. Lindor,et al.  A Pilot Trial of Pentoxifylline in Nonalcoholic Steatohepatitis , 2004, The American Journal of Gastroenterology.

[130]  G. Tarantino,et al.  Silent non-alcoholic fatty liver disease-a clinical-histological study. , 2004, Journal of hepatology.

[131]  P. Macfarlane,et al.  Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. , 2004, Diabetes.

[132]  E. Fassio,et al.  Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies , 2004, Hepatology.

[133]  L. Krugner-Higby,et al.  Mitochondria in nonalcoholic fatty liver disease. , 2004, Clinics in liver disease.

[134]  J. Horton,et al.  Molecular mediators of hepatic steatosis and liver injury. , 2004, The Journal of clinical investigation.

[135]  G. Lazaraki,et al.  Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. , 2004, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.

[136]  L. Burgart,et al.  Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial , 2004, Hepatology.

[137]  A. Işık,et al.  Metformin in the treatment of patients with non‐alcoholic steatohepatitis , 2004, Alimentary pharmacology & therapeutics.

[138]  D. Purdie,et al.  Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life , 2004, Gut.

[139]  E. Ravussin,et al.  A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM , 1995, Diabetologia.

[140]  S. Gurel,et al.  Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. , 2003, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[141]  P. Hayashi,et al.  Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis , 2003, American Journal of Gastroenterology.

[142]  J. Arenas,et al.  Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis , 2003, Hepatology.

[143]  P. Hayashi,et al.  The natural history of nonalcoholic fatty liver disease: a clinical histopathological study , 2003, American Journal of Gastroenterology.

[144]  C. McClain,et al.  Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E , 2003, Hepatology.

[145]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[146]  R. Fisher,et al.  Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values , 2003, Hepatology.

[147]  G. Marchesini,et al.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.

[148]  R. N. Macsween,et al.  Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? , 2002, Journal of clinical pathology.

[149]  U. Visco-Comandini,et al.  Metformin in non-alcoholic steatohepatitis , 2002, The Lancet.

[150]  A. Terano,et al.  Plasma transforming growth factor‐β1 level and efficacy of α‐tocopherol in patients with non‐alcoholic steatohepatitis: a pilot study , 2001, Alimentary pharmacology & therapeutics.

[151]  J. Clore,et al.  Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. , 2001, Gastroenterology.

[152]  A. Terano,et al.  Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. , 2001, Alimentary pharmacology & therapeutics.

[153]  W. Dietz,et al.  Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. , 2000, The Journal of pediatrics.

[154]  K. Batts,et al.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis , 1999, Hepatology.

[155]  H. Cortez‐Pinto,et al.  Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. , 1999, JAMA.

[156]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[157]  R. DeFronzo,et al.  Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. , 1996, The Journal of clinical endocrinology and metabolism.

[158]  G. Gores,et al.  Ursodeoxycholic acid or clofibrate in the treatment of non‐alcohol‐induced steatohepatitis: A pilot study , 1996, Hepatology.

[159]  S. Clissold,et al.  Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. , 1987, Drugs.

[160]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.

[161]  C P Price,et al.  Liver disease in patients with diabetes mellitus. , 1980, Postgraduate medical journal.